Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Appointed director
CC transcript
HAEMONETICS CORP (HAE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Haemonetics Reports First Quarter Fiscal 2024 Results&#59; Updates Fiscal 2024 Guidance"
05/11/2023 8-K Quarterly results
Docs: "Haemonetics Reports Fourth Quarter and Fiscal 2023 Results&#59; Provides Fiscal 2024 Guidance"
02/07/2023 8-K Quarterly results
Docs: "Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2023 Results&#59; Updates Fiscal 2023 Guidance"
11/07/2022 8-K Quarterly results
Docs: "Haemonetics Reports Second Quarter and First Half Fiscal 2023 Results&#59; Updates Fiscal 2023 Guidance"
08/10/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
02/08/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Haemonetics Reports Second Quarter and 1st Half Fiscal 2022 Results&#59; Updates Fiscal 2022 Guidance",
"Haemonetics Announces CFO William P. Burke’s Retirement for June 2022"
08/11/2021 8-K Quarterly results
Docs: "Haemonetics Reports First Quarter Fiscal 2022 Results&#59; Increases Guidance for Vascular Closure Revenue and Affirms All Other Fiscal 2022 Guidance&#59; Expands Operational Excellence Program"
02/02/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "Haemonetics Reports Second Quarter and 1st Half Fiscal 2021 Results"
08/04/2020 8-K/A Quarterly results
08/04/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
02/04/2020 8-K Quarterly results
Docs: "Haemonetics Reports 3rd Quarter and Year-to-Date Fiscal 2020 Results&#59; Reaffirms Revenue Guidance and Raises All Other Guidance for Fiscal 2020"
11/01/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
Docs: "Haemonetics Reports 1st Quarter Fiscal 2020 Results, Updates Fiscal 2020 Earnings Guidance and Launches Operational Excellence Program"
05/07/2019 8-K Quarterly results
Docs: "Haemonetics Reports 4th Quarter and Fiscal Year 2019 Results and Provides Fiscal Year 2020 Guidance; Board of Directors Authorizes New $500 Million Share Repurchase Program"
02/05/2019 8-K Quarterly results
11/06/2018 8-K Quarterly results
Docs: "Haemonetics Reports 2nd Quarter and 1st Half Fiscal 2019 Results; Raises Fiscal Year 2019 Guidance"
08/07/2018 8-K Quarterly results
Docs: "Haemonetics Reports 1st Quarter Fiscal 2019 Results; Affirms Fiscal Year 2019 Revenue, Adjusted EPS and Cash Flow Guidance"
05/08/2018 8-K Quarterly results
Docs: "Haemonetics Reports 4th Quarter and Fiscal Year 2018 Results and Provides Fiscal 2019 Guidance"
02/06/2018 8-K/A Quarterly results
Docs: "Haemonetics Reports 3rd Quarter Results, Raises Fiscal 2018 Guidance and Board of Directors Authorizes $260 Million Share Repurchase Program"
02/06/2018 8-K Quarterly results
Docs: "Haemonetics Reports 3rd Quarter Results, Raises Fiscal 2018 Guidance and Board of Directors Authorizes $260 Million Share Repurchase Program"
11/07/2017 8-K Quarterly results
Docs: "Haemonetics Reports 2nd Quarter Results and Raises Fiscal 2018 Guidance; Launches Strategic Initiative"
08/07/2017 8-K Quarterly results
Docs: "Haemonetics Reports 1st Quarter Fiscal 2018 Results"
05/08/2017 8-K Form 8-K - Current report
02/06/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "Haemonetics Reports 2nd Quarter and 1st Half Fiscal 2017 Results and Reaffirms Full Year Fiscal 2017 Guidance Braintree, MA, November 7, 2016 - Haemonetics Corporation reported second quarter fiscal 2017 revenue of $220.3 million, flat with the second quarter of fiscal 2016 as reported, and up 1% in constant currency. The Company reported net income of $19.8 million and $0.38 per share, up 54% and 52%, respectively, in the second quarter of fiscal 2017 compared to the same period of the prior year. Excluding restructuring, turnaround and deal amortization expenses detailed below, adjusted net income was $23.5 million and adjusted earnings per share were $0.46, up 4% and 5%, respectively, compared to the prior year second quarter. 1 First half fiscal 2017 revenue was $430.2 million, down 1%...",
"Comments on 2"
08/01/2016 8-K Form 8-K - Current report
05/02/2016 8-K Form 8-K - Current report
02/01/2016 8-K Quarterly results
Docs: "Haemonetics Reports 3rd Quarter Fiscal 2016 Revenue of $233 Million, Constant Currency Revenue Growth of 4% and 1% As Reported Revenue Growth Highlights The constant currency revenue increase in the third quarter included strong performance from identified growth drivers:"
11/04/2015 8-K Quarterly results
Docs: "Haemonetics Reports 2nd Quarter Fiscal 2016 Revenue of $220 Million and Adjusted EPS of $0.44, Affirms Recent Full Fiscal Year Guidance Product Growth Highlights 8% constant currency revenue increases in growth drivers in the second quarter, including:"
07/27/2015 8-K Quarterly results
Docs: "Haemonetics Reports 1st Quarter Fiscal 2016 Revenue of $213 Million and Adjusted EPS of $0.35, Reaffirms Full Fiscal Year Guidance"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy